ST. LOUIS, Nov. 23, 2023 (GLOBE NEWSWIRE) — Curium, a global leader in nuclear medicine, announced today the successful completion of patient enrollment in the pivotal Phase 3 ECLIPSE trial. ECLIPSE is a Phase 3, multi-center, open-label, rando
ST. LOUIS, Nov. 23, 2023 (GLOBE NEWSWIRE) -- Curium, a global leader in nuclear medicine, announced today the successful completion of patient enrollment in the pivotal Phase 3 ECLIPSE trial. Read More
Related
Share this page
Guest Posts by Easy Branches